Drilldown: Medicines

None (1) · 2-FDCK (1) · 3-HO-PCE (1) · 3-HO-PCP (1) · 3-MeO-PCE (1) · 3-MeO-PCP (1) · 4-MeO-PCP (1) · Buprenorphine (1) · Butorphanol (1) · Codeine (2) · Deschloroketamine (1) · Dextromethorphan (1) · Dextropropoxyphene (1) · Dextrorphan (1) · Dihydrocodeine (1) · Diphenidine (1) · Ephenidine (1) · Ethylmorphine (1) · Eticyclidine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Ibogaine (1) · Levorphanol (1) · LSD (1) · Meperidine (1) · Methadone (1) · Methoxetamine (1) · Nalbuphine (1) · Nitrous oxide (1) · O-PCE (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Salvia divinorum (1) · Salvinorin A (1) · Tapentadol (1) · Xenon (1)

None (22) · (multiple, generic dominant) (1) · Darvon (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · DXM (1) · DXO (1) · Nubain (1) · Nucynta (1) · Opana (1) · Spravato (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (37) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (37) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (37) · 28 mg/device (each dose uses 2 devices) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (37) · 360 mg/day (1) · 84 mg per session (1)

None (36) · Intranasal (under direct medical supervision) (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (36) · 30–60 min (PO) (1) · 30–60 minutes (1) · Within hours of first administration (1)

None (36) · 4–6 hours (1) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (36) · 2.5–3 hours (1) · 3–5 hours (1) · ~7-12 hours (1)

None (36) · 70–90% (oral) (1) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (36) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1)

None (36) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)